Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Sabra Health Care REIT (SBRA)

Sabra Q2 2025 net income rises to $0.27 per share from $0.10; updates 2025 guidance

Positive Impact 3 of 5 earnings Written later

Sabra Health Care REIT reported second-quarter 2025 net income of $0.27 per diluted share, up from $0.10 a year earlier, on total revenues of $189.2 million versus $176.1 million. It also issued 2025 guidance ranges, including net income of $0.77 to $0.79 per share and normalized FFO of $1.45 to $1.47 per share. The filing does not state the prior guidance, so the direction of the update cannot be determined from it.

Key points

  • Q2 2025 net income was $0.27 per diluted share versus $0.10 in Q2 2024; total revenues were $189.2 million versus $176.1 million.
  • Normalized FFO was $0.37 per diluted share versus $0.35; normalized AFFO was $0.38 versus $0.36.
  • 2025 guidance: net income $0.77 to $0.79 per share; normalized FFO $1.45 to $1.47 per share.
  • Board declared a quarterly dividend of $0.30 per share on August 4, 2025, payable August 29, 2025 to holders of record on August 15, 2025.

The filing

CompanySabra Health Care REIT (SBRA)
Form8-K, current report
Filed with the SECAug 4, 2025, 4:05 PM ET
Accession number0001492298-25-000030

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.